2004•Expert Opinion on Investigational DrugsRequires access

Peroxisome proliferator-activated receptor ligands in atherosclerosis

Juan F. Viles-González, Brian G. Choi, Valentı́n Fuster, Juan J. Badimón

Abstract

In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-gamma agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-alpha agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-delta and the possibilities for the role of dual-binding agonists are examined.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Peroxisome proliferator-activated receptor, PPAR agonist, Agonist, Peroxisome proliferator-activated receptor alpha, Receptor, Peroxisome, Peroxisome proliferator-activated receptor gamma, Diabetes mellitus